Very promising early results. The caveats for non scientists to be aware of is that these are not randomized trials with a placebo and all - this is just throug

Very promising early results. The caveats for non scientists to be aware of is that these are not randomized trials with a placebo and all - this is just through a mechanism called "compassionate use" that allows Gilead to give people the drug. Also, 68% of patients improved, the title implies that patients say a 68% improvement in their symptoms which is not the case, the 68% is the number of patients improved divided by total number of patients. To get a good picture of how much the drug improves outcomes compared to not having the drug administered, we need large placebo controlled randomized trials so we can get the statistical signal to see if it works and how well it works. As the paper states, those trials are underway.